MORRISTOWN, N.J., July 31 /PRNewswire/ -- Actavis Group, the international generic pharmaceuticals company, announced that it has launched Griseofulvin Oral Suspension in the United States. Distribution of the product will commence immediately.
Griseofulvin Oral Suspension USP, the generic equivalent of Ortho-McNeil’s Grifulvin(R) V, will be available in the 125mg/5mL strength. Griseofulvin is indicated for the treatment of fungal infections of the skin, fingernails and toenails.
Annual sales of Griseofulvin Oral Suspension USP in the U.S. were approximately US$38 million for the twelve months ending March 2007 according to IMS Health data.
About Actavis
Actavis is one of the world’s leading generic pharmaceutical companies specializing in the development, manufacture and sale of generic pharmaceuticals. With headquarters in Iceland, Actavis has operations in 39 countries, with 11,000 employees. The company’s market capitalization is approximately EUR3.3bn. Actavis expects 2007 sales to total EUR1.6bn, with approximately one-third of these sales coming from the United States, the company’s single largest market. In the U.S. alone, the company made 38 ANDA filings in 2006 and expects to file 40-45 in the year 2007 along with 18-20 new product launches. The company’s U.S. operations are located in New Jersey, Maryland, North Carolina and Florida.
More information about Actavis in the United States can be found at www.actavis.us.
Information in this press release may contain forward-looking statements with respect to the financial condition, results of operations and businesses of Actavis. By their nature, forward-looking statements and forecasts involve risk and uncertainty because they relate to events and depend on circumstances that will occur in the future. There are a number of factors that could cause actual results and developments to differ materially from that expressed or implied by these forward-looking statements. These factors include, among other things, exchange rate fluctuations, the risk that research and development will not yield new products that achieve commercial success, the impact of competition, price controls and price reductions, the risk of loss or expiration of patents or trade marks, difficulties of obtaining and maintaining governmental approvals for products, the risk of substantial product liability claims, exposure to environmental liability.
Actavis Group
CONTACT: David Myers, Jr., Manager, Products & Communications, +1-973-993-4503, dmyers@actavis.com, or Halldor Kristmannsson, Vice President ofCorporate Communications & IR, +1-354-535-2325, +1-354-840-3425,hkristmannsson@actavis.com, both of Actavis
Web site: http://www.actavis.us/
